



WWW.ESTRO.ORG

SATURDAY 30 APRIL 2016



	TEACHING LECTURE	TEACHING LECTURE	TEACHING LECTURE	TEACHING LECTURE	TEACHING LECTURE	TEACHING LECTURE	TEACHING LECTURE	TEACHING LECTURE		
08:00 – 08:40	Technology assessment	CRISPR/CAS technology: from cells to mice to stem cell therapy	Partial breast irradiation: who, when and how?	ТВС	Role of brachytherapy in the management of paediatric tumours	Challenges in MR guidance	Patient specific quality assurance in proton therapy	Side effects – actual clinical benefit in particular considerations, from photons to protons		
	SYMPOSIUM	SYMPOSIUM	SYMPOSIUM	SYMPOSIUM	SYMPOSIUM	SYMPOSIUM	SYMPOSIUM	SYMPOSIUM	POSTER VIEWING]
08:45-10:00	Selection of patients for proton therapy Selection of patients for proton therapy: a clinician's view Selection of patients for proton therapy: a physicist's view Future selection practice for proton therapy: selection of patients based on treatment planning comparison and NTCP-modelling	Mitigating normal tissue toxicity ACE inhibitors and lung / cardiac / vascular damage Mitigation of skin fibrosis Mitigation of lung fibrosis by anti- macrophage strategy	Regional nodal irradiation for breast cancer The axilla - less surgery, more radiotherapy? The internal mammary chain- should we treat it in every node-positive patient? Technical approaches to regional LN irradiation	Assessment and management of rectal morbidity Morbidity scoring Measuring anorectal toxicity and function Rectal spacers to minimise morbidity in radiotherapy for prostate cancer	Towards user oriented QA procedures for treatment verification How to ensure the quality in brachytherapy treatment planning systems? Imaging Dose verification	Robust and accurate functional MRI for radiotherapy Needs and technical requirements for functional MRI in radiotherapy Variation in DCE-MRI methodology and its implications for radiotherapy Importance of b-value selection and geometrical accuracy in DW- MRI for radiotherapy	Joint ESTRO-IAEA efforts on dosimetry, QA and audit for advanced treatment techniques New code of practice for small- and non standard fields Which dosimetric uncertainties in small fields are clinically acceptable for IMRT/VMAT? IAEA external audits for advanced radiotherapy - lessons learnt and their relevance for industrialised countries	Strategies for treatment planning Comparisons of dose planning for photon and proton When to re-plan - how to use modern techniques - a practical perspective Auto planning: consequences for the department		-
10:00 - 10:30	COFFEE BREAK									1
	SYMPOSIUM	PROFFERED PAPERS	PROFFERED PAPERS	PROFFERED PAPERS	PROFFERED PAPERS	PROFFERED PAPERS	PROFFERED PAPERS	PROFFERED PAPERS	POSTER VIEWING	
10:30 - 11:30	Protons or heavy ions? Radiobiological benefits of protons and heavy ions - advantages and disadvantages Physical advantages of particles: protons vs. heavy ions, what is certain what is not?									
	How strong is the current clinical evidence for protons and heavy ions ?									
11:45 - 12:20	PRESIDENTIAL SYMPOSIUM									
12:20 - 13.00	EMMANUEL VAN DER SCHUEREN AWARD L	ECTURE								
13:00 - 14:30	LUNCH AND INDUSTRY SYMPOSIA									
	SYMPOSIUM	SYMPOSIUM	DEBATE	SYMPOSIUM	SYMPOSIUM	SYMPOSIUM	DEBATE	SYMPOSIUM	POSTER VIEWING	MULTI TUM
14:30 – 15:45	SYMPOSIUM Hot topics in SABR: time for randomised clinical trials? Do we need randomised clinical data to justify the use of SABR for primary and oligometastatic cancer? Preclinical and clinical data on the radiobiological mechanism for the efficacy of SABR Technical developments in high precision radiotherapy: a new era for clinical SABR	Tumour targeting - considering normal tissue biology Tumour - normal tissue models for individualised tumour screening The role of ATM and p53 in normal tissue radiation response DNA repair in stem cells A radiation system biology view of radiation sensitivity of normal and tumour	DEBATE This house believes that treatment intensification should be pursued in locally advanced NSCLC	SYMPOSIUM Active surveillance for low risk prostate cancer: to treat or not to treat? Does (very) low risk prostate cancer really exist? The role of imaging in active surveillance Active surveillance: challenges and perspectives. The clinician point of view	SYMPOSIUM Achieving excellence in image guided brachytherapy Physician training in contouring Physicist training in 3D dose planning New avenues for training with e-learning	SYMPOSIUM Imaging markers for response prediction and assessment Imaging markers for response prediction: the clinical need Response prediction in rectal cancer using PET radiomics Imaging of normal liver tissue for <i>in vivo</i> verification and function assessment	DEBATE No need for in-room MR-guidance for the main tumour sites!	SYMPOSIUM Additional tools for contouring Functional and molecular imaging techniques and personalised radiotherapy General recontouring with deformal registration Automation of contouring	POSTER VIEWING	MULT TUM
	SYMPOSIUM Hot topics in SABR: time for randomised clinical trials? Do we need randomised clinical data to justify the use of SABR for primary and oligometastatic cancer? Preclinical and clinical data on the radiobiological mechanism for the efficacy of SABR Technical developments in high precision radiotherapy: a new era for clinical SABR trials?	Tumour targeting - considering normal tissue biology Tumour - normal tissue models for individualised tumour screening The role of ATM and p53 in normal tissue radiation response DNA repair in stem cells A radiation system biology view of	This house believes that treatment intensification should be pursued in	Active surveillance for low risk prostate cancer: to treat or not to treat? Does (very) low risk prostate cancer really exist? The role of imaging in active surveillance Active surveillance: challenges and	Achieving excellence in image guided brachytherapy Physician training in contouring Physicist training in 3D dose planning New avenues for training with	Imaging markers for response prediction and assessment Imaging markers for response prediction: the clinical need Response prediction in rectal cancer using PET radiomics Imaging of normal liver tissue for <i>in vivo</i> verification and function	No need for in-room MR-guidance for the main	Additional tools for contouring Functional and molecular imaging techniques and personalised radiotherapy General recontouring with deformal registration	POSTER VIEWING	
14:30 – 15:45 15:45 – 16:15	SYMPOSIUM Hot topics in SABR: time for randomised clinical trials? Do we need randomised clinical data to justify the use of SABR for primary and oligometastatic cancer? Preclinical and clinical data on the radiobiological mechanism for the efficacy of SABR Technical developments in high precision radiotherapy: a new era for clinical SABR trials?	Tumour targeting - considering normal tissue biology Tumour - normal tissue models for individualised tumour screening The role of ATM and p53 in normal tissue radiation response DNA repair in stem cells A radiation system biology view of radiation sensitivity of normal and tumour cells	This house believes that treatment intensification should be pursued in locally advanced NSCLC	Active surveillance for low risk prostate cancer: to treat or not to treat? Does (very) low risk prostate cancer really exist? The role of imaging in active surveillance Active surveillance: challenges and perspectives. The clinician point of view	Achieving excellence in image guided brachytherapy Physician training in contouring Physicist training in 3D dose planning New avenues for training with e-learning	Imaging markers for response prediction and assessment Imaging markers for response prediction: the clinical need Response prediction in rectal cancer using PET radiomics Imaging of normal liver tissue for <i>in vivo</i> verification and function assessment	No need for in-room MR-guidance for the main tumour sites!	Additional tools for contouring Functional and molecular imaging techniques and personalised radiotherapy General recontouring with deformal registration Automation of contouring		
	SYMPOSIUM Hot topics in SABR: time for randomised clinical trials? Do we need randomised clinical data to justify the use of SABR for primary and oligometastatic cancer? Preclinical and clinical data on the radiobiological mechanism for the efficacy of SABR Technical developments in high precision radiotherapy: a new era for clinical SABR trials? COFFEE BREAK SYMPOSIUM MR-PET What MR-PET can offer for radiation	Tumour targeting - considering normal tissue biology Tumour - normal tissue models for individualised tumour screening The role of ATM and p53 in normal tissue radiation response DNA repair in stem cells A radiation system biology view of radiation sensitivity of normal and tumour	This house believes that treatment intensification should be pursued in	Active surveillance for low risk prostate cancer: to treat or not to treat? Does (very) low risk prostate cancer really exist? The role of imaging in active surveillance Active surveillance: challenges and	Achieving excellence in image guided brachytherapy Physician training in contouring Physicist training in 3D dose planning New avenues for training with	Imaging markers for response prediction and assessment Imaging markers for response prediction: the clinical need Response prediction in rectal cancer using PET radiomics Imaging of normal liver tissue for <i>in vivo</i> verification and function	No need for in-room MR-guidance for the main	Additional tools for contouring Functional and molecular imaging techniques and personalised radiotherapy General recontouring with deformal registration	POSTER VIEWING POSTER VIEWING	
15:45 - 16:15 16:15 - 17:15	SYMPOSIUM Hot topics in SABR: time for randomised clinical trials? Do we need randomised clinical data to justify the use of SABR for primary and oligometastatic cancer? Preclinical and clinical data on the radiobiological mechanism for the efficacy of SABR Technical developments in high precision radiotherapy: a new era for clinical SABR trials? COFFEE BREAK SYMPOSIUM MR-PET What MR-PET can offer for radiation oncology How to use MR-PET for radiation oncology Making hybrid MR-PET ready for radiation	Tumour targeting - considering normal tissue biology Tumour - normal tissue models for individualised tumour screening The role of ATM and p53 in normal tissue radiation response DNA repair in stem cells A radiation system biology view of radiation sensitivity of normal and tumour cells	This house believes that treatment intensification should be pursued in locally advanced NSCLC	Active surveillance for low risk prostate cancer: to treat or not to treat? Does (very) low risk prostate cancer really exist? The role of imaging in active surveillance Active surveillance: challenges and perspectives. The clinician point of view	Achieving excellence in image guided brachytherapy Physician training in contouring Physicist training in 3D dose planning New avenues for training with e-learning	Imaging markers for response prediction and assessment Imaging markers for response prediction: the clinical need Response prediction in rectal cancer using PET radiomics Imaging of normal liver tissue for <i>in vivo</i> verification and function assessment	No need for in-room MR-guidance for the main tumour sites!	Additional tools for contouring Functional and molecular imaging techniques and personalised radiotherapy General recontouring with deformal registration Automation of contouring		







BRACHYTHERAPY SESSION

SUNDAY 1 MAY 2016



	TEACHING LECTURE	TEACHING LECTURE	TEACHING LECTURE	TEACHING LECTURE	TEACHING LECTURE	TEACHING LECTURE	TEACHING LECTURE	TEACHING LECTURE	TEACHING L
08:00 - 08:40	Pitfalls and risks of standardisation in high- tech radiotherapy	DNA repair and response for beginners	Anal cancer: current guidelines and remaining questions	Radiotherapy and immune- therapy on the biological basis	Underestimated importance of intraluminal brachytherapy: bronchus, oesophageal, anorectal and hepatobiliary duct cancer	Big data in radiotherapy: technology, challenges and opportunities	The role of dosimetry audit in safety, quality and best practice for external beam and brachytherapy	General introduction to head and neck radiotherapy	e-Learnin Professior Radiation O what, why ar
	SYMPOSIUM	SYMPOSIUM	SYMPOSIUM	SYMPOSIUM	SYMPOSIUM	SYMPOSIUM	PROFFERED PAPERS	SYMPOSIUM	SYMPOS
08:45-10:00	Quality beyond accuracy: are we failing to see the forest for the trees? Did the higher accuracy in treatment delivery translate into noticeable clinical improvements? The patient: an active partner in quality and safety process in radiotherapy Beyond accuracy: how can medical physics help improve treatment quality?	Targeting DNA repair / DDR pre-clinical evidence Tumour-specific radiosensitisation by ATR inhibitors Preclinical evaluations of RT- ATM & ATR inhibitor combinations Realising the full potential of DNA damage response inhibition in the treatment of cancer	New approaches in rectal cancer How to delineate the CTV for rectal cancer? An international consensus The way forward in organ preservation strategies for rectal cancer Consequences of bowel cancer screening programmes	Changing paradigm in the management of kidney cancer Partial nefrectomy: indication and results Any role for radiotherapy in the management of kidney cancer? New insights in the medical management of kidney cancer	Modern techniques for old indications Robotic surgery and brachytherapy New techniques in brachytherapy for head and neck Image guided brachytherapy in vaginal cancer	Quantitative imaging to individualise radiotherapy Tissue characterisation using quantitative radiomics Image-based radiobiological tumour control probability modelling Validation of imaging with histology: implications for dose prescriptions		Head and neck: reduction of margins and side effects Contouring of normal tissues in head and neck radiotherapy The ESTRO perspective - a guideline for positioning of head and neck patients Late effects in patients treated for head and neck cancer	The future of 1 Oncology pu views through and Red tele Green Jou Red Jour How to do a good review
10:00 - 10:30	COFFEE BREAK								
10:30 - 11:30	SYMPOSIUM QA in clinical trials: processes, impact and future perspectives How effective is current clinical trial QA? How does QA impact on clinical outcomes? What will we need for future QA in clinical trials?	PROFFERED PAPERS	PROFFERED PAPERS	PROFFERED PAPERS	PROFFERED PAPERS	PROFFERED PAPERS	PROFFERED PAPERS	PROFFERED PAPERS	
						ll			1
11:45 - 12:00	DONAL HOLLYWOOD AWARD								
11:45 - 12:00 12:00 - 12.45		RS							
									YOUNG LUNCH S Planning ahee finish your resid project with a
12:00 - 12.45	HIGHLIGHTS OF PROFFERED PAPE		SYMPOSIUM	DEBATE	DEBATE	SYMPOSIUM	SYMPOSIUM	SYMPOSIUM	Planning ahea finish your resid
12:00 - 12.45	HIGHLIGHTS OF PROFFERED PAPE	Α	SYMPOSIUM Radiotherapy of prostate cancer: technical challenges Extreme hypofractionation: indications and results Focal strategies: ready for prime time? Brachytherapy as a boost: the way to go?	DEBATE This house believes that SBRT should become the standard of care for T1 and small T2 NSCLC tumours	DEBATE Is brachytherapy the best for partial breast irradiation? Multicatheter brachytherapy is the best for PBI IORT is the best for PBI IMRT is the best for PBI Dosimetric pros and cons of available PBI techniques	SYMPOSIUM New challenges in modelling dose-volume effects Evaluating the impact of clinical uncertainties on NTCP models in brachytherapy Incorporation of imaging- based features into predictive models of toxicity Growing importance of data-mining methods to select dosimetric/clinical variables in integrated predictive models of toxicity	SYMPOSIUM Automated treatment plan generation in the clinical routine Automated treatment plan generation - the Zurich experience Automated treatment plan generation - the Milan experience Fully automated treatment plan generation using Erasmus-iCycle - the Rotterdam experience	SYMPOSIUM Elderly and radiation therapy Geriatric assessment is a requirement to effectively provide a quality radiotherapy service to the older person Enhancing continuity of care and symptom management with the use of palliative radiotherapy treatment summaries (PaRTS) Treatment choices in the elderly; focus on breast cancer	Planning ahea finish your resic project with a SYMPOS A joint session Radiation Om National Soo YROO What is the You Committee and w for young radiati profession The Young Radiati Group of E The French Socie Radiation Om AIRO (Italian A Radiation Oncol Grouy The British In Radiato
12:00 - 12.45	HIGHLIGHTS OF PROFFERED PAPE LUNCH AND INDUSTRY SYMPOSIA SYMPOSIUM Standardisation in clinical practice Guideline-based contouring and clinical audit systems Standardisation and treatment planning Potentials and challenges of automated contouring in treatment planning Implementation of new standards in your department: an RTT	SYMPOSIUM DNA repair inhibition and RT: moving towards clinic Challenges in combining CT with PARP inhibitors Results of phase I trials combining PARP inhibition and radiotherapy in multiple sites Phase I results PARPi + RT +	Radiotherapy of prostate cancer: technical challenges Extreme hypofractionation: indications and results Focal strategies: ready for prime time? Brachytherapy as a boost: the	This house believes that SBRT should become the standard of care for T1 and	Is brachytherapy the best for partial breast irradiation? Multicatheter brachytherapy is the best for PBI IORT is the best for PBI IMRT is the best for PBI Dosimetric pros and cons of	New challenges in modelling dose-volume effects Evaluating the impact of clinical uncertainties on NTCP models in brachytherapy Incorporation of imaging- based features into predictive models of toxicity Growing importance of data-mining methods to select dosimetric/clinical variables in integrated predictive models	Automated treatment plan generation in the clinical routine Automated treatment plan generation - the Zurich experience Automated treatment plan generation - the Milan experience Fully automated treatment plan generation using Erasmus-iCycle - the	Elderly and radiation therapy Geriatric assessment is a requirement to effectively provide a quality radiotherapy service to the older person Enhancing continuity of care and symptom management with the use of palliative radiotherapy treatment summaries (PaRTS)	Planning ahee finish your resic project with a SYMPOS A joint session Radiation On National Soo YROO What is the You Committee and for young radiati profession The Young Radiati Group of E The French Socie Radiation On AIRO (Italian A Radiation Oncol Group The British In Radiolo Round table wi
12:00 - 12.45	HIGHLIGHTS OF PROFFERED PAPE LUNCH AND INDUSTRY SYMPOSIA SYMPOSIUM Standardisation in clinical practice Guideline-based contouring and clinical audit systems Standardisation and treatment planning Potentials and challenges of automated contouring in treatment planning Implementation of new standards in your department: an RTT perspective COFFEE BREAK SYMPOSIUM Health Economics in Radiation Oncology	SYMPOSIUM DNA repair inhibition and RT: moving towards clinic Challenges in combining CT with PARP inhibitors Results of phase I trials combining PARP inhibition and radiotherapy in multiple sites Phase I results PARPi + RT +	Radiotherapy of prostate cancer: technical challenges Extreme hypofractionation: indications and results Focal strategies: ready for prime time? Brachytherapy as a boost: the	This house believes that SBRT should become the standard of care for T1 and	Is brachytherapy the best for partial breast irradiation? Multicatheter brachytherapy is the best for PBI IORT is the best for PBI IMRT is the best for PBI Dosimetric pros and cons of	New challenges in modelling dose-volume effects Evaluating the impact of clinical uncertainties on NTCP models in brachytherapy Incorporation of imaging- based features into predictive models of toxicity Growing importance of data-mining methods to select dosimetric/clinical variables in integrated predictive models	Automated treatment plan generation in the clinical routine Automated treatment plan generation - the Zurich experience Automated treatment plan generation - the Milan experience Fully automated treatment plan generation using Erasmus-iCycle - the	Elderly and radiation therapy Geriatric assessment is a requirement to effectively provide a quality radiotherapy service to the older person Enhancing continuity of care and symptom management with the use of palliative radiotherapy treatment summaries (PaRTS)	Planning ahee finish your resis project with a SYMPOS A joint session Radiation Or National So YRO What is the You Committee and v for young radiati profession The Young Radiat Group of E The French Socie Radiation Onco Group The Brench Socie Radiation Onco Group The British In Radioto Onco Group The British In Radiation Onco Group The British In Radioto Onco Group The British In State The British In Radioto Onco Group The British In State The Brit State The British In State The Brit State
12:00 - 12.45 13:00 - 14:30 14:30 - 15:45 14:30 - 15:45 15:45 - 16:15 16:15 - 17:15	HIGHLIGHTS OF PROFFERED PAPE LUNCH AND INDUSTRY SYMPOSIA SYMPOSIUM Standardisation in clinical practice Guideline-based contouring and clinical audit systems Standardisation and treatment planning Potentials and challenges of automated contouring in treatment planning Implementation of new standards in your department: an RTT perspective COFFEE BREAK SYMPOSIUM Health Economics in Radiation Oncology (HERO)	SYMPOSIUM DNA repair inhibition and RT: moving towards clinic Challenges in combining CT with PARP inhibitors Results of phase I trials combining PARP inhibition and radiotherapy in multiple sites Phase I results PARPi + RT + Cetuximab in HNSCC	Radiotherapy of prostate cancer: technical challenges Extreme hypofractionation: indications and results Focal strategies: ready for prime time? Brachytherapy as a boost: the way to go?	This house believes that SBRT should become the standard of care for T1 and small T2 NSCLC tumours	Is brachytherapy the best for partial breast irradiation? Multicatheter brachytherapy is the best for PBI IORT is the best for PBI IMRT is the best for PBI Dosimetric pros and cons of available PBI techniques	New challenges in modelling dose-volume effects Evaluating the impact of clinical uncertainties on NTCP models in brachytherapy Incorporation of imaging- based features into predictive models of toxicity Growing importance of data-minig methods to select dosimetric/clinical variables in integrated predictive models of toxicity	Automated treatment plan generation in the clinical routine Automated treatment plan generation - the Zurich experience Automated treatment plan generation - the Milan experience Fully automated treatment plan generation using Erasmus-iCycle - the Rotterdam experience	Elderly and radiation therapy Geriatric assessment is a requirement to effectively provide a quality radiotherapy service to the older person Enhancing continuity of care and symptom management with the use of palliative radiotherapy treatment summaries (PaRTS) Treatment choices in the elderly; focus on breast cancer	Planning ahee finish your resic project with a SYMPOS A joint session Radiation On National Soo YROO What is the You Committee and for young radiati profession The Young Radiati Group of E The French Socie Radiation On AIRO (Italian A Radiation Oncol Group The British In Radiolo Round table wi







BRACHYTHERAPY SESSION



YOUNG SCIENTIST SESSION

IING LECTURE		
earning for essionals in ion Oncology: why and how?		
MPOSIUM	POSTER VIEWING	
re of Radiation gy publishing: ough the Green ed telescopes een Journal 		
	POSTER VIEWING	
NCH SYMPOSIUM g ahead: how to r residency / PhD with a job offer		
g ahead: how to r residency / PhD	POSTER VIEWING	MULTIDISCIPLINARY TUMOUR BOARD
g ahead: how to r residency / PhD with a job offer MPOSIUM ession of Young on Oncologists al Societies & YROG he Young ESTRO and what can it do radiation oncology fessionnals? Radiation Oncology up of EORTC h Society of Young on Oncologists alian Association Oncology) Young Group	POSTER VIEWING	MULTIDISCIPLINARY TUMOUR BOARD Rectal cancer
g ahead: how to r residency / PhD with a job offer MPOSIUM ession of Young on Oncologists al Societies & YROG he Young ESTRO and what can it do radiation oncology fessionnals? Radiation Oncology up of EORTC h Society of Young on Oncologists alian Association Oncology) Young	POSTER VIEWING	TUMOUR BOARD
g ahead: how to r residency / PhD with a job offer MPOSIUM ession of Young on Oncologists al Societies & YROG he Young ESTRO radiation Oncology fessionnals? Radiation Oncology of EORTC h Society of Young on Oncologists alian Association Oncology Young Group tish Institute of tadiology able with present	POSTER VIEWING	TUMOUR BOARD
g ahead: how to r residency / PhD with a job offer MPOSIUM ession of Young on Oncologists al Societies & YROG he Young ESTRO radiation Oncology fessionnals? Radiation Oncology of EORTC h Society of Young on Oncologists alian Association Oncology Young Group tish Institute of tadiology able with present	POSTER VIEWING	TUMOUR BOARD
g ahead: how to r residency / PhD with a job offer MPOSIUM ession of Young on Oncologists al Societies & YROG he Young ESTRO e and what can it do radiation oncology pof EORTC h Society of Young on Oncologists alian Association Oncology Young Group tish Institute of tadiology be with present lational Societies		TUMOUR BOARD Rectal cancer
g ahead: how to r residency / PhD with a job offer MPOSIUM ession of Young on Oncologists al Societies & YROG he Young ESTRO and what can it do radiation oncology fessionnals? Radiation Oncology of EORTC h Society of Young on Oncologists alian Association Oncology Young Group tish Institute of tadiology able with present lational Societies G RECEPTION reception and rom the Young		TUMOUR BOARD Rectal cancer

MONDAY 2 MAY 2016



	TEACHING LECTURE	TEACHING LECTURE	TEACHING LECTURE	TEACHING LECTURE	TEACHING LECTURE	TEACHING LECTURE	TEACHING LECTURE	TE
08:00-08:40	How to bring QUANTEC into the 21st century?	Shared decision making	Genetic mouse models for cancer research	SBRT for oligometastatic disease	Advanced treatment strategies for head and neck cancer	Dose to water vs. dose to tissue: issues for treatment planning and dose measurement	Nanodosimetry: from radiation physics to radiation biology	Brac pelvic perspe
	SYMPOSIUM	TEACHING LECTURE	SYMPOSIUM	SYMPOSIUM	SYMPOSIUM	SYMPOSIUM	PROFFERED PAPERS	
08:45-10:00	Adaptive radiotherapy for coping with anatomical variations: hope or hype? Overview of clinical practice of ART for abdominal and pelvic tumours The challenges of ART from a physician's perspective The practical "cost" of adaptive radiotherapy (in personnel time, patient time, etc)	Time is not on our side: cardiovascular toxicity after radiotherapy The risk of cardiovascular disease after breast cancer treatment: the clinician's point of view Predicting cardiac toxicity after breast irradiation: new quantitative data and new challenges Active surveillance for cardiovascular disease after Hodgkin's lymphoma	Emerging biomarkers Circulating tumour cells as biomarkers in lung radiotherapy The fall and raise of yH2AX as predictive radiotherapy biomarkers Genomic breast cancer subtype classification for response prediction Genomic subtypes in prostate cancer and its influence in treatment response	SBRT for oligometastatic disease Combining SBRT and immunotherapy: a promising approach? SBRT for metastatic disease: how far can and should we go? Abdominal-pelvic targets	Head and neck: state-of- the-art and directions for future research Molecular targeting with radiotherapy Immunotherapy for HNSCC: an emerging paradigm? Proton therapy in HNSCC: better than IMRT?	SBRT in lung - choices and their impact on related uncertainties Dosimetric aspects and robustness in optimisation of SBRT for small lung tumours Does the prescription isodose matter? To use or not to use the LQ model at "high" radiation doses		Adapti Brachyt Li Clinical Imple
10:00 - 10:30	COFFEE BREAK							
	SYMPOSIUM	SYMPOSIUM	PROFFERED PAPERS	PROFFERED PAPERS	PROFFERED PAPERS	PROFFERED PAPERS	PROFFERED PAPERS	PR
10:30 - 11:30	Modern ART based on functional / biological imaging Functional imaging for ART, biological bases and potential impact on clinical outcome Adaptive radiation therapy by the example of head and neck cancer. is there any role for a RTT? Dosimetric benefit of replanning: when does	Secondary cancer after radiotherapy: from cancer registries to clinical implications Secondary cancer risks assessed from epidemiology studies Modelling of secondary cancer risks Clinical implications of secondary cancer risks in pediatric and adult patients						
	the new treatment plan make a difference? ARTFORCE project							
11:45 - 12:30	the new treatment plan make a difference?							
11:45 - 12:30 12:30 - 13.00	the new treatment plan make a difference? ARTFORCE project							
	the new treatment plan make a difference? ARTFORCE project SELECTED RANDOMISED TRIALS							
12:30 - 13.00	the new treatment plan make a difference? ARTFORCE project SELECTED RANDOMISED TRIALS KLAAS BREUR AWARD LECTURE	SYMPOSIUM	SYMPOSIUM	DEBATE	JOINT SYMPOSIUM	SYMPOSIUM	SYMPOSIUM	
12:30 - 13.00	the new treatment plan make a difference? ARTFORCE project SELECTED RANDOMISED TRIALS KLAAS BREUR AWARD LECTURE LUNCH AND INDUSTRY SYMPOSIA	SYMPOSIUM Communication with patients Patient's perspective Healthcare professional's perspective RTT/Nurse's perspective Interaction between patients and professionals: a psycho-oncologist's view	SYMPOSIUM Imaging biology Imaging biology: what do we really see? Genetics and imaging: a pas-de-deux in response prediction Molecular imaging for radiotherapy optimisation	DEBATE This house believes that centralised large radiotherapy units will provide the best academia and the best treatment quality	JOINT SYMPOSIUM ESTRO-ILROG Modern radiotherapy in Jymphoma Indications to radiotherapy for lymphoma in 2016: what is standard of care and what remains controversial? New concepts for lymphoma radiotherapy and the use of advanced technology Modern maging and radiotherapy in lymphoma	SYMPOSIUM Functional / biological imaging and radiotherapy physicists: new requests/challenges and the need for better and more specific training	SYMPOSIUM Small animal irradiation Preclinical radiotherapy technology, dosimetry and treatment planning Radiation biology studies with a small animal irradiator: results from the research programme at Johns Hopkins University How do we select meaningful pre-clinical models for studies in radiation biology?	Focus of Bladd inform An eval intrapr stabilit Validati decisi of
12:30 - 13.00 13:00 - 14:30	the new treatment plan make a difference? ARTFORCE project SELECTED RANDOMISED TRIALS KLAAS BREUR AWARD LECTURE LUNCH AND INDUSTRY SYMPOSIA JOINT SYMPOSIUM ESTRO-ASTRO In room adaptive imaging with a focus on MRI MRI Linac: physics perspective Adaptive planning, dose delivery and verification with MRI based brachytherapy Clinical experience with low-field MR guided teletherapy	Communication with patients Patient's perspective Healthcare professional's perspective RTT/Nurse's perspective Interaction between patients and	Imaging biology Imaging biology: what do we really see? Genetics and imaging: a pas-de-deux in response prediction Molecular imaging for radiotherapy	This house believes that centralised large radiotherapy units will provide the best academia and the	ESTRO-ILROG Modern radiotherapy in lymphoma Indications to radiotherapy for lymphoma in 2016: what is standard of care and what remains controversial? New concepts for lymphoma radiotherapy and the use of advanced technology Modern imaging and	Functional / biological imaging and radiotherapy physicists: new requests/challenges and the need for better and more specific	Small animal irradiation Preclinical radiotherapy technology, dosimetry and treatment planning Radiation biology studies with a small animal irradiator: results from the research programme at Johns Hopkins University How do we select meaningful pre-clinical models for studies in	Bladd inform An eval intrapr stabilit Validat decisi
12:30 - 13.00 13:00 - 14:30 14:30 - 16:00	the new treatment plan make a difference? ARTFORCE project SELECTED RANDOMISED TRIALS KLAAS BREUR AWARD LECTURE LUNCH AND INDUSTRY SYMPOSIA JOINT SYMPOSIUM ESTRO-ASTRO In room adaptive imaging with a focus on MRI MRI Linac: physics perspective Adaptive planning, dose delivery and verification with MRI based brachytherapy Clinical experience with low-field MR guided teletherapy Linac-based MRI device	Communication with patients Patient's perspective Healthcare professional's perspective RTT/Nurse's perspective Interaction between patients and	Imaging biology Imaging biology: what do we really see? Genetics and imaging: a pas-de-deux in response prediction Molecular imaging for radiotherapy	This house believes that centralised large radiotherapy units will provide the best academia and the	ESTRO-ILROG Modern radiotherapy in lymphoma Indications to radiotherapy for lymphoma in 2016: what is standard of care and what remains controversial? New concepts for lymphoma radiotherapy and the use of advanced technology Modern imaging and	Functional / biological imaging and radiotherapy physicists: new requests/challenges and the need for better and more specific	Small animal irradiation Preclinical radiotherapy technology, dosimetry and treatment planning Radiation biology studies with a small animal irradiator: results from the research programme at Johns Hopkins University How do we select meaningful pre-clinical models for studies in	Bladd inform An eval intrapr stabilit Validati decisi
12:30 - 13.00 13:00 - 14:30 14:30 - 16:00	the new treatment plan make a difference? ARTFORCE project SELECTED RANDOMISED TRIALS KLAAS BREUR AWARD LECTURE LUNCH AND INDUSTRY SYMPOSIA JOINT SYMPOSIUM ESTRO-ASTRO In room adaptive imaging with a focus on MRI MRI Linac: physics perspective Adaptive planning, dose delivery and verification with MRI based brachytherapy Clinical experience with low-field MR guided teletherapy Linac-based MRI device	Communication with patients Patient's perspective Healthcare professional's perspective RTT/Nurse's perspective Interaction between patients and professionals: a psycho-oncologist's view	Imaging biology Imaging biology: what do we really see? Genetics and imaging: a pas-de-deux in response prediction Molecular imaging for radiotherapy optimisation	This house believes that centralised large radiotherapy units will provide the best academia and the best treatment quality	ESTRO-ILROG Modern radiotherapy in lymphoma Indications to radiotherapy for lymphoma in 2016: what is standard of care and what remains controversial? New concepts for lymphoma radiotherapy and the use of advanced technology Modern imaging and radiotherapy in lymphoma	Functional / biological imaging and radiotherapy physicists: new requests/challenges and the need for better and more specific training	Small animal irradiation Preclinical radiotherapy technology, dosimetry and treatment planning Radiation biology studies with a small animal irradiator: results from the research programme at Johns Hopkins University How do we select meaningful pre-clinical models for studies in radiation biology?	Bladd inform An evai intrapr stabilit Validat decisi o
12:30 - 13.00 13:00 - 14:30 14:30 - 16:00 16:00 - 16:30	the new treatment plan make a difference? ARTFORCE project SELECTED RANDOMISED TRIALS KLAAS BREUR AWARD LECTURE LUNCH AND INDUSTRY SYMPOSIA JOINT SYMPOSIUM ESTRO-ASTRO In room adaptive imaging with a focus on MRI MRI Linac: physics perspective Adaptive planning, dose delivery and verification with MRI based brachytherapy Clinical experience with low-field MR guided teletherapy Linac-based MRI device COFFEE BREAK SYMPOSIUM Dose painting: those pending issues The promises of dose painting Biological rationale of dose painting: is it clear?	Communication with patients Patient's perspective Healthcare professional's perspective RTT/Nurse's perspective Interaction between patients and professionals: a psycho-oncologist's view SYMPOSIUM SYMPOSIUM ACROP ACROP: General procedures, SOPs and current status Clinical guidelines, update and introduction of recent clinical guidelines, update and introduction of recent	Imaging biology Imaging biology: what do we really see? Genetics and imaging: a pas-de-deux in response prediction Molecular imaging for radiotherapy optimisation	This house believes that centralised large radiotherapy units will provide the best academia and the best treatment quality	ESTRO-ILROG Modern radiotherapy in lymphoma Indications to radiotherapy for lymphoma in 2016: what is standard of care and what remains controversial? New concepts for lymphoma radiotherapy and the use of advanced technology Modern imaging and radiotherapy in lymphoma	Functional / biological imaging and radiotherapy physicists: new requests/challenges and the need for better and more specific training	Small animal irradiation Preclinical radiotherapy technology, dosimetry and treatment planning Radiation biology studies with a small animal irradiator: results from the research programme at Johns Hopkins University How do we select meaningful pre-clinical models for studies in radiation biology?	Bladd inform An eval intrapr stabilit Validati decisi c







BRACHYTHERAPY SESSION

Brachytherapy for the elvic region: status and erspective for the future SYMPOSIUM POSTER VIEWING aptive treatments in the pelvic region hytherapy pelvic and MRI-Linac combination ical implementation of ART for cervix nplementation of ART in rectum POSTER VIEWING POSTER VIEWING MULTIDISCIPLINARY TUMOUR BOARD Oligometastatic disease cus on the pelvic region Bladder filling, effects and formation about the filling n evaluation of GoldAnchor traprostatic fiducial marker ability during radiotherapy idation of a prostate cancer ecision aid tool for shared decision making POSTER VIEWING

TUESDAY 3 MAY 2016



TEACHING LECTURE	TEACHING LECTURE	TEACHING LECTURE	TEACHING LECTURE	TEACHING LECTURE	TEACHING LECTURE	TE
The new 'Rs' in radiation biology	Texture analysis of medical images	Heavy ion therapy: physical, radiobiological and clinical aspects	Neuroendocrine tumours – personalised diagnosis and treatment using radiolabelled peptides	Radiotherapy for paediatric brain tumours	Role and validation of deformable image registration in clinical practice	VMAT QA: ai
SYMPOSIUM	SYMPOSIUM	SYMPOSIUM	SYMPOSIUM	SYMPOSIUM	SYMPOSIUM	
New concepts of tumour radioresistance Immune system and radiation response The contribution of cancer stem cells to tumour radioresistance Novel insights in radioresistance of head and neck cancer	Towards Personalised Radiation Oncology (PRO) New technologies for genomic tumour profiling Gene expression profiles in tumours for PRO GWAS SNPs and normal tissue toxicity for PRO Integrative data analysis for PRO	The tumour in 3D: the role of tumour microenvironment Relevance of 3D cultures to address radiation response and novel RT combination strategies The potential of normal tissue organoid cultures The impact of a novel 3D cell culture model of glioblastoma on radiation and drug- radiation responses Radiation promotes immunological recognition	WBRT for brain metastases - the end of an era? Whole brain radiotherapy - the end of an era in NSCLC only or, in all radio-resistant malignancies Focal radiotherapy for multiple brain metastases Role of systemic therapy in the treatment of brain metastases	Radiotherapy "autovaccination" with systemic immune modulators for modern immunotherapy Should the combined treatment be part of our field of knowledge? Radiotherapy for immunotherapy: optimising the doses and fractionation Radiotherapy vs. chemotherapy induced "autovaccination": results and toxicity	ART in particle therapy The need for adaptive approaches in proton therapy compared to photons Cone beam CT as a tool for adaptive techniques in proton therapy Adaptive techniques in proton therapy of the lung In vivo range estimation and adaptive particle therapy	The future The need of aut fu Automated Q Autom Automation in
COFFEE BREAK						
SYMPOSIUM	SYMPOSIUM	SYMPOSIUM	SYMPOSIUM	SYMPOSIUM	SYMPOSIUM	
Combining radiotherapy with molecular targeted agents: learning from successes and failures Lessons learned from clinical trials combining radiotherapy and EGFR antibodies Challenges combining radiotherapy with immunotherapy Combining radiotherapy with modulators of VEGF signaling: getting the right balance	Radiomics - the future of radiotherapy? Imaging-Genomics: identifying molecular phenotypes by integrating radiomics and genomics data PET/CT heterogeneity quantification through texture analysis: potential role for prognostic and predictive models The potential of radiomics for radiotherapy individualisation	Radiobiology of proton / carbon / heavy ions Gene expression alterations to carbon ion and X-irradiation Normal tissue response in particle therapy Preclinical proton therapy studies	New insights in treating vertebral metastases Recent progresses in interventional radiology What are the limits of minimally invasive surgery? How to optimise the curative potential of SBRT?	IMRT, the new standard in treatment of gynaecological, lung and breast cancers? Organ motion: is it an obstacle to the use of IMRT as a standard technique for gynaecological cancers? IMRT for lung cancer: current status and future developments IMRT in breast cancers: dream or reality?	Plan of the day (PotD): current status PotD brachytherapy PotD external beam overview current practice PotD ViewRay – MR image-guided plan of the day	We don't need doing
This house believes that in 2020 hypo-						
	The new 'Rs' in radiation biology SYMPOSIUM SYMPOSIUM Account and radiation response The contribution of cancer stem cells to tumour radioresistance Novel insights in radioresistance of head and neck cancer COFFEE BREAK SYMPOSIUM Combining radiotherapy with molecular targeted agents: learning from successes and failures Lessons learned from clinical trials combining radiotherapy and EGFR antibodies Challenges combining radiotherapy with molecular targeted agents: learning from successes and failures Challenges combining radiotherapy with molecular targeted agents: learning from successes and failures Challenges combining radiotherapy with molecular targeted agents and the failures Challenges combining radiotherapy with molecular targeted from clinical trials combining radiotherapy and EGFR antibodies Challenges combining radiotherapy with molecular targeted agents Combining radiotherapy with modulators of breg signaling: getting the right balance CLOSING DEBATE	The new 'Rs' in radiation biology Texture analysis of medical images SYMPOSIUM SYMPOSIUM New concepts of tumour radioresistance Towards Personalised Radiation Oncology (PRO) Immune system and radiation response The contribution of cancer stem cells to tumour radioresistance Novel insights in radioresistance of head and neck cancer Server the contribution of cancer stem cells to tumour radioresistance of head and neck cancer COFFEE BREAK SYMPOSIUM Combining radiotherapy with molecular targeted agents: learning from successes and failures SYMPOSIUM Lessons learned from clinical trials combining radiotherapy with molecular targeted signaling: getting the right balance Der TCT heterogeneity quantification through texture analysis: potential role for prognostic and predictive models Challenges combining radiotherapy with modulators of VEGF signaling: getting the right balance PET/CT heterogeneity quantification through texture analysis: potential role for prognostic and predictive models Chosing radiotherapy with modulators of VEGF signaling: getting the right balance The potential of radiomics for radiotherapy individualisation	The new 'Rs' in radiation biologyTexture analysis of medical imagesHeavy ion therapy: physical, radiobiological and clinical aspectsSYMPOSIUMSYMPOSIUMSYMPOSIUMNew concepts of tumour radioresistanceTowards Personalised Radiation Oncology (PRO)The tumour in 3D: the role of tumour recircorevironmentImmune system and radiation responseNew technologies for genomic tumour profilingRetexace of 3D cultures to addressNovel insights in radioresistance of head and neck cancerNew technologies for PRORetexace of 3D cultures to addressNovel insights in radioresistance of head and neck cancerGWAS SNPs and normal tissue toxicity for PROThe impact of a novel SD cell culture model of glioblastoma on radiation and drug-radiation responsesCOFFEE BREAKSYMPOSIUMSYMPOSIUMSYMPOSIUMCombining radiotherapy with molecular targeted agents: learning rom successes and failuresRadiomics - the future of radiotherapy?Gene expression alteriation or and X-irradiationChallenges combining radiotherapy with immunoherapyPET/CT hetrogeneity quantification through texture analysis. potential of forgenontics identifying molecular targeted agents: learning radiotherapy with immunoherapyPET/CT hetrogeneity quantification through texture analysis. potential of for adiotherapy with modulators of VEGF signaling: getting the right balancePET/CT hetrogeneity quantification through texture analysis. potential for fordionics for radiotherapy: IndividualisationNormal tissue response in particle therapyConsbining radiotherapy with WEGF signaling: getting the right balancePetotential of radiotherapy: IndividualisationNormal tissue response in particle therapyConsbining	The new 'Rs' in radiation biologyTexture analysis of medical imagesHeavy ion therapy: physical, radiobiological and clinical aspectsNeuroendocrine tumours - presonalised diagnosis and treatment using radiolabelled peptidesSYMPOSIUMSYMPOSIUMSYMPOSIUMSYMPOSIUMNew concepts of tumour radioresistanceTowards Personalised Radiation Oncolegy (PRO)The tumour in 3D: the role of tumour radioresistanceWBRT for brain metastases - the end of an era'.Immune system and radiation response The contribution of cancer stem cells to tumour radioresistance of the contribution of cancer stem cells to tumour radioresistance of the contribution of cancer stem cells to tumour radioresistance of head and neck cancerThe tumours in table erapoine and novel RT radiation response radio novel RT response response res	The new 'Rs' in radiation biologyTexture analysis of medical imagesHeavy ion therapy; physical, radiobiological and clinical aspectsNeuroendocrine tumours, personalised diagnosis and treatment using radiobioledled psptidesRadiotherapy for paediatric brain tumoursSYMPOSIUMSYMPOSIUMSYMPOSIUMSYMPOSIUMSYMPOSIUMSYMPOSIUMSYMPOSIUMNew concepts of tumour radio resistanceTowards Personalised Radiation Donology (PRO)Towards Personalised Radiation ProfileTowards Personalised Radiation ProfileMBRT for brain radiotherapy interrod of an era?Wolk Tior brain radiotherapy interrod of an era?Radiotherapy for allocidate radio with generation radiotherapy interrod of an era?Wolk Tior brain materialses - the end of an era?Radiotherapy for allocidate radio with generation radiotherapy interrod of an era?Wolk Tior brain materialses - the end of an era?Radiotherapy for allocidate radio with generation radio with generation radiotherapy interrod of an era?Wolk Tior brain materialses - the end of an era?Radiotherapy for allocidate radio with generation radio with generation radioting radiotherapy interrod oral radiation responsesWolk Fain materialses - the end of an era?Radiotherapy for allocidate radio with generation responsesWolk Fain materialses - the end of an era?Radiotherapy for multiple train multiple radio with generation radio with generation radio with generation radio with generation responsesNot insights in nationersitance of the and nack cancerSVMPOSUMSVMPOSUMSVMPOSUMSVMPOSUMSVMPOSUMSVMPOSUMSVMPOSUMContreat	Increw "8" in radiation biologyExture analysis of nedical imagesHeavy ion herapy: physical, radiobiological and clinical aspectsNeuroendocrine tumours, personalised diagnosis and treatment image radiobielingRedicherapy for pacitarity brain tumoursRelicherapy for pacitarity brain tumoursSYMPOSIMSYMPOSIMSYMPOSIMSYMPOSIMSYMPOSIMSYMPOSIMNew concepts of tumour radioresitance nationes rational radius response profilingTowards Personalised Radiation Oncology (PRO) Dispersonalised Radiation Oncology (PRO) Dispersonalised response radius response radius on response radius response radius on response radius







BRACHYTHERAPY SESSION

YOUNG SCIENTIST SESSION

